Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 311

1.

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

Hou MM, Liu X, Wheler J, Naing A, Hong D, Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, Kurzrock R, Fu S.

Oncotarget. 2014 Oct 29. [Epub ahead of print]

PMID:
25426553
[PubMed - as supplied by publisher]
Free Article
2.

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.

Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R.

Oncotarget. 2014 Nov 15;5(21):10280-92.

PMID:
25373733
[PubMed - in process]
Free Article
3.

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.

Randall JM, Millard F, Kurzrock R.

Cancer Metastasis Rev. 2014 Dec;33(4):1109-24. doi: 10.1007/s10555-014-9533-1.

PMID:
25365943
[PubMed - in process]
4.

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R.

Invest New Drugs. 2014 Nov 4. [Epub ahead of print]

PMID:
25363205
[PubMed - as supplied by publisher]
5.

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Venook AP, Arcila ME, Benson AB 3rd, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML.

J Natl Compr Canc Netw. 2014 Nov;12(11):1629-49.

PMID:
25361808
[PubMed - in process]
6.

Unique molecular landscapes in cancer: implications for individualized, curated drug combinations.

Wheler J, Lee JJ, Kurzrock R.

Cancer Res. 2014 Dec 15;74(24):7181-4. doi: 10.1158/0008-5472.CAN-14-2329. Epub 2014 Oct 17.

PMID:
25326492
[PubMed - in process]
7.

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic.

Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2014 Dec 15;20(24):6336-45. doi: 10.1158/1078-0432.CCR-14-1293. Epub 2014 Oct 17.

PMID:
25326232
[PubMed - in process]
8.

Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders.

Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O.

Cancer Discov. 2014 Oct 16. pii: CD-14-0742. [Epub ahead of print]

PMID:
25324352
[PubMed - as supplied by publisher]
9.

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R.

Invest New Drugs. 2014 Oct 18. [Epub ahead of print]

PMID:
25323060
[PubMed - as supplied by publisher]
10.

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic.

Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS.

Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14.

PMID:
25316815
[PubMed - in process]
11.

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.

Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM.

Oncotarget. 2014 Oct 15;5(19):8937-46.

PMID:
25313136
[PubMed - in process]
Free PMC Article
12.

BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer.

Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R.

Thyroid. 2014 Oct 6. [Epub ahead of print]

PMID:
25285888
[PubMed - as supplied by publisher]
13.

Triple-negative breast cancer patients treated at MD anderson cancer center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.

Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ.

Mol Cancer Ther. 2014 Dec;13(12):3175-84. doi: 10.1158/1535-7163.MCT-14-0358. Epub 2014 Sep 24.

PMID:
25253784
[PubMed - in process]
14.

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.

Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R.

PLoS One. 2014 Aug 13;9(8):e93676. doi: 10.1371/journal.pone.0093676. eCollection 2014.

PMID:
25119929
[PubMed - in process]
Free PMC Article
15.

MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors.

Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Genitourin Cancer. 2014 Jul 3. pii: S1558-7673(14)00128-1. doi: 10.1016/j.clgc.2014.06.017. [Epub ahead of print]

PMID:
25087088
[PubMed - as supplied by publisher]
16.

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples.

Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II.

Clin Epigenetics. 2014 Jul 3;6(1):13. doi: 10.1186/1868-7083-6-13. eCollection 2014.

PMID:
25024751
[PubMed]
Free PMC Article
17.

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.

Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG.

Oncotarget. 2014 Jun 15;5(11):3607-10.

PMID:
25003820
[PubMed - in process]
Free PMC Article
18.

Characteristics and survival of patients with advanced cancer and p53 mutations.

Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM.

Oncotarget. 2014 Jun 15;5(11):3871-9.

PMID:
25003695
[PubMed - in process]
Free PMC Article
19.

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.

Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D.

Clin Cancer Res. 2014 Sep 15;20(18):4827-36. doi: 10.1158/1078-0432.CCR-14-0603. Epub 2014 Jul 1.

PMID:
24987059
[PubMed - in process]
20.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.

Clin Cancer Res. 2014 Sep 1;20(17):4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23.

PMID:
24958809
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk